中国上海5岁以下儿童轮状病毒疫苗效果与覆盖率:一项检测阴性病例对照研究
该研究基于上海五家医院的前瞻性监测,采用检测阴性病例对照设计评估轮状病毒疫苗效果。兰州羊轮状病毒疫苗部分接种(2剂)效果为49.09%(95%CI:1.69%~73.64%);RotaTeq全程接种效果在多变量分析中为89.46%(95%CI:55.03%~97.53%)。2011至2022年出生、轮状病毒阴性腹泻患儿中任意剂次接种覆盖率为49.78%,RotaTeq上市后覆盖率从45.02%升至61.77%。
要点
- RotaTeq全程接种在多变量分析中疫苗效果为89.46%(95%CI:55.03%~97.53%)。
- 兰州羊轮状病毒疫苗部分接种(2剂)效果为49.09%(95%CI:1.69%~73.64%)。
- 轮状病毒疫苗任意剂次覆盖率为49.78%,RotaTeq上市后从45.02%升至61.77%。
核心结论
- RotaTeq显示出强大的保护效果,而兰州羊轮状病毒疫苗对上海儿童轻至中度轮状病毒腹泻提供一定水平保护。
- 作者估计上海儿童对自费(非免疫规划)轮状病毒疫苗的覆盖率较高。
- 作者推荐年龄符合条件的儿童完成轮状病毒疫苗全程接种。
- 作者认为有必要进一步开展轮状病毒疫苗上市后研究,为国内引入轮状病毒疫苗的决策提供依据。
研究设计与样本
- 基于前瞻性监测的检测阴性病例对照研究,在上海五家医院5岁及以下腹泻患者中开展。
- 病例与对照依据粪便样本实时荧光定量逆转录聚合酶链反应(rRT-PCR)轮状病毒结果定义。
- 采用匹配和非匹配病例对照设计,使用逻辑回归模型并调整发病年龄和轮状病毒流行季节。
主要发现
- 兰州羊轮状病毒疫苗专项分析(247例病例、2191例对照)中,部分接种(2剂)在多变量分析中疫苗效果为49.09%(95%CI:1.69%~73.64%)。
- RotaTeq专项分析(42例病例、523例对照)中,全程接种疫苗效果在单变量分析为87.13%(95%CI:45.87%~96.94%),多变量分析为89.46%(95%CI:55.03%~97.53%),匹配分析为85.69%(95%CI:33.43%~96.93%)。
- 2011至2022年出生、轮状病毒阴性腹泻的2893例患者中,任意剂次疫苗接种覆盖率为49.78%。
- 2018年RotaTeq获批后,该覆盖率从45.02%升至61.77%。
关键数值与推荐
- RotaTeq全程接种多变量分析疫苗效果89.46%(95%CI:55.03%~97.53%)。
- 兰州羊轮状病毒疫苗部分接种(2剂)多变量分析疫苗效果49.09%(95%CI:1.69%~73.64%)。
- 轮状病毒疫苗任意剂次覆盖率49.78%,RotaTeq上市后从45.02%升至61.77%。
临床怎么用
- 作者推荐年龄符合条件的儿童完成轮状病毒疫苗全程接种。
- 作者认为有必要进一步开展轮状病毒疫苗上市后研究,为国内引入轮状病毒疫苗的决策提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The number of post-marketing studies assessing the vaccine effectiveness (VE) of the Lanzhou lamb rotavirus vaccine (LLR, licensed in 2000 exclusively in China) and the oral human attenuated pentavalent rotavirus vaccine (RotaTeq, licensed in China in 2018) in China is limited. METHODS: A test-negative case-control study based on prospective surveillance was conducted among diarrhea patients aged 5 years and younger at five hospitals in Shanghai, China. Cases and controls were defined based on the results of real-time fluorescent quantitative reverse transcription polymerase chain reaction (rRT-PCR) of fecal samples for rotavirus. Both matched and unmatched case-control study designs were employed using logistic regression models, with adjustments for age at onset age and the rotavirus epidemic season. RESULTS: In the LLR-specific analysis (247 cases, 2191 controls), the VE of partial LLR vaccination (2 doses) was 49.09 % (95 % CI: 1.69 % ∼ 73.64 %) in multivariate analyses. In the RotaTeq-specific analysis (42 cases and 523 controls), the VE of complete RotaTeq vaccination was 87.13 % (95 % CI: 45.87 % ∼ 96.94 %), 89.46 % (95 % CI: 55.03 % ∼ 97.53 %), and 85.69 % (95 % CI: 33.43 % ∼ 96.93 %) respectively in univariate, multivariate, and matched analyses, respectively. The vaccination coverage for any dose among 2893 patients with rotavirus-negative diarrhea born between 2011 and 2022 was 49.78 %. Following the licensure of RotaTeq in 2018, this coverage increased from 45.02 % to 61.77 %. CONCLUSIONS: RotaTeq demonstrates a robust protective effectiveness, while LLR provides a certain level of protection against mild to moderate rotavirus diarrhea in children in Shanghai. For privately purchased (non-NIP) vaccines, we estimate that the coverage for rotavirus vaccines among children in Shanghai is high. Complete rotavirus vaccination is recommended for age-eligible children. Further post-marketing research on rotavirus vaccines is necessary to inform decision-making regarding the introduction of rotavirus vaccination in China.
引用
- Gong X, Huang Z, Zheng Y, et al. Rotavirus vaccine effectiveness and coverage among children younger than 5 years old in Shanghai, China: A test-negative case control study. Vaccine. 2025. PMID: 39809089. doi:10.1016/j.vaccine.2025.126731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。